What's the Difference Between Wegovy and Ozempic? Same Drug, Different FDA Approvals, Different Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist, and work through identical mechanisms
• Wegovy is FDA-approved for chronic weight management at a maximum dose of 2.4 mg weekly; Ozempic is approved for type 2 diabetes at 0.5 mg, 1 mg, or 2 mg weekly
• The 2.4 mg dose produces approximately 15% total body weight loss over 68 weeks; the 1 mg dose produces approximately 6-7% weight loss as a secondary outcome in diabetes trials
• Insurance coverage differs dramatically: most plans cover Ozempic for diabetes but exclude Wegovy for weight loss, creating a $900-$1,300 monthly out-of-pocket gap

Direct answer (40-60 words)

Wegovy and Ozempic are the same molecule (semaglutide) manufactured by the same company (Novo Nordisk) but FDA-approved for different indications. Wegovy is approved for obesity at 2.4 mg weekly. Ozempic is approved for type 2 diabetes at 0.5 to 2 mg weekly. The higher Wegovy dose produces roughly double the weight loss of the highest Ozempic dose.

Table of contents

1. The core distinction: indication and dose, not molecule
2. The clinical trial data: STEP vs SUSTAIN programs
3. Side-by-side comparison: dosing, titration, and outcomes
4. Why the same drug has two brand names
5. The insurance coverage gap and why it exists
6. What most articles get wrong about "off-label" Ozempic for weight loss
7. Compounded semaglutide: the third option that bypasses the brand-name question
8. When you should choose Ozempic over Wegovy (the diabetes-first scenario)
9. The FormBlends clinical pattern: what drives patients toward compounded options
10. Decision tree: which semaglutide product matches your situation
11. FAQ
12. Sources

The core distinction: indication and dose, not molecule

Wegovy and Ozempic contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The molecular structure is identical. The manufacturing process is identical. The mechanism of action is identical. Both slow gastric emptying, increase satiety signaling in the hypothalamus, and reduce appetite through central and peripheral pathways.

The difference is regulatory, not pharmacological.

Wegovy received FDA approval in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approved dose is 2.4 mg subcutaneously once weekly after a 16-week titration schedule.

Ozempic received FDA approval in December 2017 for improving glycemic control in adults with type 2 diabetes. The approved doses are 0.5 mg, 1 mg, or 2 mg subcutaneously once weekly. Weight loss is documented in the Ozempic trials but listed as a secondary outcome, not the primary indication.

The FDA does not approve drugs. It approves specific uses of drugs at specific doses based on submitted trial data. Novo Nordisk ran separate clinical trial programs for each indication and submitted separate New Drug Applications (NDAs). The agency granted separate approvals with separate labeling.

This regulatory structure creates the pricing and coverage environment patients encounter. The drug is the same. The approval pathway determines whether insurance pays.

The clinical trial data: STEP vs SUSTAIN programs

Novo Nordisk's semaglutide development split into two parallel trial programs:

SUSTAIN trials (Ozempic, diabetes indication):

• SUSTAIN 1-10, enrolling patients with type 2 diabetes
• Primary endpoint: HbA1c reduction
• Secondary endpoint: body weight change
• Dose range tested: 0.5 mg and 1 mg weekly in most trials; 2 mg added in later trials
• Published 2017-2021

STEP trials (Wegovy, obesity indication):

• STEP 1-5, enrolling patients with obesity or overweight, most without diabetes
• Primary endpoint: percent body weight change from baseline
• Dose tested: 2.4 mg weekly (with comparison arms at lower doses in some trials)
• Published 2021-2022

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) is the major Wegovy study. It enrolled 1,961 adults with BMI ≥30 or BMI ≥27 with comorbidities, without diabetes. At 68 weeks:

• Semaglutide 2.4 mg: 14.9% mean weight loss
• Placebo: 2.4% mean weight loss

The SUSTAIN 6 trial (Marso et al., New England Journal of Medicine, 2016) enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk. At 104 weeks:

• Semaglutide 0.5 mg: 3.6 kg (approximately 3.5%) mean weight loss
• Semaglutide 1 mg: 4.9 kg (approximately 4.7%) mean weight loss
• Placebo: 0.7 kg weight loss

The SUSTAIN FORTE trial (Frías et al., Diabetes Care, 2021) tested the 2 mg dose in diabetes patients. At 40 weeks:

• Semaglutide 2 mg: 6.2 kg (approximately 6.7%) mean weight loss
• Semaglutide 1 mg: 5.0 kg (approximately 5.4%) mean weight loss

The dose-response relationship is clear. Higher semaglutide doses produce greater weight loss. The 2.4 mg Wegovy dose produces roughly double the weight loss of the 1 mg Ozempic dose in head-to-head comparisons within the same trial (STEP 2, which enrolled diabetes patients, showed 9.6% weight loss at 2.4 mg vs 7.0% at 1 mg).

Side-by-side comparison: dosing, titration, and outcomes

Feature	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
FDA-approved indication	Type 2 diabetes	Chronic weight management
Available doses	0.25 mg, 0.5 mg, 1 mg, 2 mg	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Maintenance dose	0.5 mg, 1 mg, or 2 mg weekly	2.4 mg weekly
Titration schedule	4 weeks at 0.25 mg, then escalate to 0.5 or 1 mg; optional escalation to 2 mg after 4+ weeks at 1 mg	4 weeks each at 0.25, 0.5, 1, 1.7 mg, then 2.4 mg (16-week titration)
Mean weight loss (primary trials)	6.2 kg (6.7%) at 2 mg dose in SUSTAIN FORTE	14.9% at 2.4 mg dose in STEP 1
Mean HbA1c reduction	1.4 to 1.8 percentage points (SUSTAIN trials)	0.6 to 0.9 percentage points in patients with prediabetes (STEP trials)
Pen delivery system	0.25/0.5 mg pen, 1 mg pen, 2 mg pen	0.25/0.5 mg pen, 1/1.7 mg pen, 2.4 mg pen
List price (monthly, 2026)	Approximately $900-$1,000	Approximately $1,300-$1,400
Typical insurance coverage	Covered for diabetes with prior authorization	Excluded by most plans for weight loss

The titration schedules differ because the target doses differ. Wegovy's 16-week titration to 2.4 mg is longer than Ozempic's typical 8-week titration to 1 mg, reflecting the need to minimize gastrointestinal side effects at higher doses.

Both medications are injected subcutaneously once weekly, on the same day each week, at any time of day, with or without food. Both use pre-filled single-dose pens.

Why the same drug has two brand names

The two-brand strategy is standard pharmaceutical practice when a single molecule has multiple FDA-approved indications with different target patient populations.

Novo Nordisk's rationale:

1. Separate marketing and positioning. Diabetes drugs are marketed to endocrinologists and primary care physicians managing glucose. Weight-loss drugs are marketed to bariatric specialists, obesity medicine physicians, and direct-to-consumer channels. Separate brands allow separate messaging.

1. Pricing flexibility. Obesity drugs historically command higher prices than diabetes drugs in the U.S. market. Separate brands allow separate pricing without creating internal price competition.

1. Insurance navigation. Diabetes medications have established coverage pathways under pharmacy benefits. Obesity medications face coverage exclusions under many plans. Separate brands clarify which indication is being treated, reducing prior authorization confusion.

1. Patent and exclusivity management. Separate NDAs create separate exclusivity periods and separate patent landscapes, extending total market protection time.

The strategy is not unique to semaglutide. Allergan marketed the same botulinum toxin as Botox (cosmetic) and Botox Therapeutic (medical). Eli Lilly markets insulin lispro as Humalog (diabetes) and nothing else, but the same corporate strategy applies across the portfolio.

Patients experience this as confusion. Clinicians experience it as a prior authorization burden. Payers experience it as cost containment use. The pharmaceutical company experiences it as revenue optimization.

The insurance coverage gap and why it exists

The coverage gap is the single biggest practical difference between Wegovy and Ozempic for patients without diabetes.

Ozempic coverage (for FDA-approved diabetes indication):

• Covered by approximately 85% of commercial insurance plans
• Covered by Medicare Part D (with formulary variation and prior authorization)
• Typical patient copay: $25 to $75 per month with insurance
• Prior authorization usually requires documented diabetes diagnosis (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL) and trial of metformin

Wegovy coverage (for FDA-approved obesity indication):

• Covered by approximately 25% of commercial insurance plans as of 2026
• Excluded from Medicare Part D coverage by federal law (the Medicare Part D statute explicitly excludes weight-loss drugs)
• When covered, typical copay: $25 to $100 per month
• When not covered, full out-of-pocket cost: $1,300 to $1,400 per month

The Medicare exclusion dates to the 2003 Medicare Modernization Act, which prohibited Part D coverage of drugs used for weight loss or weight gain. The exclusion was written in response to concerns about fen-phen and older appetite suppressants. It remains in effect despite the clinical evidence base for GLP-1 medications.

The commercial insurance exclusion reflects plan design decisions. Employers and insurers exclude obesity drugs to control pharmacy spending. The clinical argument for coverage (obesity is a chronic disease, GLP-1s reduce cardiovascular events, long-term cost offsets) has not yet overcome the short-term budget impact in most plan negotiations.

This coverage structure creates predictable patient behavior: patients with diabetes get Ozempic covered. Patients without diabetes but with obesity face a $1,300/month Wegovy bill, see Ozempic costs $75/month for their diabetic neighbor, and ask their provider to prescribe Ozempic off-label.

What most articles get wrong about "off-label" Ozempic for weight loss

Most patient-facing content states: "Doctors can prescribe Ozempic off-label for weight loss, and many do."

This is technically true but misleading in three ways.

Misconception 1: Off-label prescribing bypasses the coverage problem.

Off-label prescribing is legal and common. Prescribing Ozempic for weight loss in a patient without diabetes is within a physician's scope of practice. But insurance coverage is determined by FDA-approved indications, not prescriber intent.

If a patient does not have a documented diabetes diagnosis, the prior authorization for Ozempic will be denied, regardless of what the prescriber writes in the notes. The claim will process as "off-label use, not a covered indication." The patient receives a denial letter and a $900 bill.

Some patients believe "off-label" means "insurance will cover it if my doctor says it's medically necessary." It does not. It means the prescriber is using the drug outside its FDA-approved indication, and the insurance company will almost certainly not pay.

Misconception 2: Ozempic at 1 mg is equivalent to Wegovy for weight loss.

The STEP 2 trial directly compared semaglutide 1 mg vs 2.4 mg in patients with diabetes. At 68 weeks, the 2.4 mg group lost 9.6% body weight; the 1 mg group lost 7.0%. The difference is statistically and clinically significant.

Prescribing Ozempic 1 mg off-label for weight loss delivers about 70% of the weight loss of the FDA-approved Wegovy dose. For some patients, that is sufficient. For others, it is not. Framing the two as interchangeable misrepresents the dose-response data.

Misconception 3: The 2 mg Ozempic dose is the same as 2.4 mg Wegovy.

Ozempic is available in a 2 mg dose as of 2022. The SUSTAIN FORTE trial showed meaningful weight loss at 2 mg. But 2 mg is not 2.4 mg. The STEP trials tested 2.4 mg specifically. The difference is small (17% lower dose) but not zero.

More importantly, the Ozempic 2 mg pen is approved for diabetes, not obesity. Prescribing it off-label for weight loss triggers the same coverage denials as the 1 mg dose. The patient pays out of pocket either way, at which point the question becomes: why pay $900 for Ozempic 2 mg when Wegovy 2.4 mg costs $1,300 and delivers the FDA-approved weight-loss dose?

The answer is usually: patients do not pay either. They switch to compounded semaglutide, which costs $200 to $400 per month and is available at the full 2.4 mg dose.

Compounded semaglutide: the third option that bypasses the brand-name question

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved. It is not manufactured by Novo Nordisk. It is not branded as Ozempic or Wegovy.

Compounding pharmacies source semaglutide powder (the active pharmaceutical ingredient) from FDA-registered suppliers, reconstitute it in bacteriostatic water or saline, and dispense it in multi-dose vials with separate insulin syringes or in pre-filled syringes.

Compounded semaglutide became widely available in 2022-2023 when Novo Nordisk's manufacturing capacity could not meet demand, and the FDA placed Wegovy and Ozempic on the drug shortage list. Under federal law (Section 503A of the Food, Drug, and Cosmetic Act), compounding pharmacies are permitted to prepare compounded versions of drugs in shortage.

As of April 2026, Wegovy remains on the FDA shortage list intermittently, and compounded semaglutide remains legally available.

Key differences between compounded semaglutide and brand-name products:

Feature	Brand-name (Ozempic/Wegovy)	Compounded semaglutide
FDA approval	Yes (for specific indications)	No (compounded drugs are not FDA-approved)
Manufacturing	Novo Nordisk, FDA-inspected facility	State-licensed compounding pharmacy, state-inspected
Dosing precision	Pre-filled pen, fixed dose per injection	Vial or pre-filled syringe, dose drawn by patient or pre-measured by pharmacy
Cost	$900-$1,400/month list price	$200-$400/month typical retail price
Insurance coverage	Varies by indication and plan	Rarely covered; mostly cash-pay
Availability during shortage	Limited	Widely available

Compounded semaglutide is not interchangeable with Ozempic or Wegovy. It has not undergone the same FDA review. Dosing accuracy depends on pharmacy compounding practices and patient technique. But for patients facing $1,300/month out-of-pocket costs or unable to access brand-name products due to shortages, compounded semaglutide is the economically rational choice.

FormBlends connects patients with licensed providers who prescribe compounded semaglutide and with compounding pharmacies that prepare it. The clinical outcomes in our patient population mirror the published STEP trial data at equivalent doses, which is consistent with the expectation that semaglutide is semaglutide, regardless of who manufactures it.

When you should choose Ozempic over Wegovy (the diabetes-first scenario)

If you have type 2 diabetes, Ozempic is the appropriate first choice, even if weight loss is your primary goal.

The reasoning:

1. Insurance will cover it. Ozempic for diabetes is a covered indication. Wegovy for weight loss in a patient with diabetes is often excluded even though the patient qualifies by BMI. Payers view diabetes as the higher-priority indication.

1. The diabetes indication is the on-label use. Prescribing Ozempic for a patient with diabetes avoids the off-label question entirely. The prior authorization is straightforward.

1. The 1 mg or 2 mg Ozempic dose produces clinically significant weight loss. The STEP 2 trial enrolled patients with diabetes and showed 7.0% weight loss at 1 mg and 9.6% at 2.4 mg (tested as an investigational dose in that trial, now available as Wegovy). For many patients, 7% weight loss is sufficient to improve blood pressure, lipids, and mobility.

1. You can escalate to Wegovy later if needed. If the Ozempic 1 mg dose improves your HbA1c but you want more weight loss, you can ask your provider to switch you to Wegovy 2.4 mg. Some insurers will cover the switch if diabetes control is stable and weight loss is inadequate. Others will deny it. But starting with Ozempic establishes the treatment relationship and the track record of tolerability.

The clinical decision tree for a patient with diabetes and obesity is: start Ozempic, titrate to 1 mg, assess HbA1c and weight loss at 6 months. If HbA1c is at goal and weight loss is satisfactory, continue Ozempic 1 mg. If HbA1c is at goal but weight loss is inadequate, request Wegovy 2.4 mg (or switch to compounded semaglutide 2.4 mg if insurance denies). If HbA1c is not at goal, escalate Ozempic to 2 mg or add a second diabetes medication.

The FormBlends clinical pattern: what drives patients toward compounded options

Across the patient population working with FormBlends providers, three patterns consistently drive patients toward compounded semaglutide rather than brand-name Ozempic or Wegovy:

Pattern 1: The insurance denial after prior authorization.

The patient has obesity without diabetes. The provider prescribes Wegovy. The pharmacy submits the claim. The insurance company denies it as "not a covered benefit" or "excluded under plan terms." The patient receives a letter stating the out-of-pocket cost is $1,349. The patient calls the provider and asks for an alternative. The provider prescribes compounded semaglutide at $295/month. The patient starts treatment.

This is the most common pathway. It accounts for roughly 60% of new compounded semaglutide patients in our network.

Pattern 2: The Ozempic off-label denial.

The patient has obesity without diabetes. The provider prescribes Ozempic 1 mg, hoping insurance will cover it. The prior authorization form asks for diabetes diagnosis code and recent HbA1c. The provider cannot provide them because the patient does not have diabetes. The claim is denied. The patient faces the same $900 out-of-pocket cost. The patient switches to compounded semaglutide.

This pattern has become less common as providers learn that off-label Ozempic does not bypass coverage restrictions. It still accounts for about 20% of new patients.

Pattern 3: The shortage-driven switch.

The patient has a valid Wegovy prescription and insurance coverage. The pharmacy is out of stock. The manufacturer backorder estimate is 6 to 8 weeks. The patient is currently on Wegovy 1.7 mg, halfway through titration. Stopping for 8 weeks means restarting titration from 0.25 mg. The patient asks the provider for a bridge option. The provider prescribes compounded semaglutide at the equivalent dose. The patient continues treatment without interruption.

This pattern surged in 2022-2023 during the peak shortage period. It remains relevant in 2026 during intermittent supply constraints.

The common thread: patients are willing to use brand-name products when insurance covers them and pharmacies stock them. When either condition fails, patients switch to compounded options. The clinical outcome data does not show a difference in efficacy or safety between brand-name and compounded semaglutide at equivalent doses, which reinforces the economic logic of the switch.

Decision tree: which semaglutide product matches your situation

Start here: Do you have type 2 diabetes (HbA1c ≥6.5% or prior diagnosis)?

→ Yes, I have diabetes.

• Does your insurance cover Ozempic with prior authorization?
• Yes: Start Ozempic. Titrate to 1 mg. Assess HbA1c and weight at 6 months. If weight loss is insufficient, discuss escalation to 2 mg or switch to Wegovy/compounded semaglutide 2.4 mg.
• No: Ask your provider about compounded semaglutide. Titrate to 1 mg or 2.4 mg depending on weight-loss goals.

→ No, I do not have diabetes. I am seeking treatment for obesity or overweight with comorbidities.

• Does your insurance cover Wegovy for weight loss?
• Yes (rare): Start Wegovy. Titrate to 2.4 mg per the FDA-approved schedule.
• No (common): What is your out-of-pocket budget?
• I can pay $1,300/month: Pay cash for Wegovy 2.4 mg.
• I can pay $200-$400/month: Ask your provider about compounded semaglutide 2.4 mg.
• I cannot afford either: Discuss alternative GLP-1 options (liraglutide has a lower cost tier in some plans) or non-GLP-1 weight-loss medications.

→ I am currently on Wegovy or Ozempic, but my pharmacy is out of stock.

• Is the backorder longer than 4 weeks?
• Yes: Ask your provider about switching to compounded semaglutide at your current dose to avoid restarting titration.
• No: Wait for restock if tolerable, or switch to compounded semaglutide temporarily.

→ I want the lowest cost option regardless of brand.

• Compounded semaglutide is the lowest-cost option at $200-$400/month retail. Work with a provider who prescribes compounded formulations and a pharmacy that prepares them.

FAQ

Are Wegovy and Ozempic the same drug? Yes. Both contain semaglutide, a GLP-1 receptor agonist. The molecular structure, mechanism of action, and manufacturer (Novo Nordisk) are identical. The difference is FDA-approved indication and maximum dose.

Why is Wegovy more expensive than Ozempic? Wegovy's list price is approximately $1,300-$1,400/month vs Ozempic's $900-$1,000/month. The price difference reflects separate pricing strategies for obesity vs diabetes indications. Obesity drugs historically command higher prices in the U.S. market, and Novo Nordisk prices Wegovy accordingly.

Can I use Ozempic for weight loss if I don't have diabetes? Legally, yes. A physician can prescribe Ozempic off-label for weight loss. Practically, insurance will not cover it without a diabetes diagnosis, leaving you with a $900/month out-of-pocket cost. Most patients in that situation switch to compounded semaglutide at $200-$400/month.

Is Wegovy stronger than Ozempic? Wegovy's maximum dose (2.4 mg weekly) is higher than Ozempic's typical maximum dose (1 mg weekly, with 2 mg available as of 2022). Higher doses produce greater weight loss. The STEP trials showed 14.9% weight loss at 2.4 mg vs approximately 7% at 1 mg in diabetes patients.

Does insurance cover Wegovy? About 25% of commercial insurance plans cover Wegovy for obesity as of 2026. Medicare Part D does not cover it due to a federal statutory exclusion of weight-loss drugs. When covered, prior authorization typically requires BMI ≥30 or BMI ≥27 with comorbidities.

Does insurance cover Ozempic for weight loss? No. Insurance covers Ozempic only for its FDA-approved indication (type 2 diabetes). If you do not have diabetes, prior authorization will be denied even if your doctor prescribes it for weight loss.

What is compounded semaglutide? Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and not manufactured by Novo Nordisk. It costs $200-$400/month and is available at doses up to 2.4 mg weekly.

Is compounded semaglutide as effective as Wegovy? Compounded semaglutide has not undergone FDA review, so there are no head-to-head trials comparing it to Wegovy. Clinical experience suggests equivalent efficacy at equivalent doses, which is consistent with the expectation that semaglutide's mechanism of action does not depend on the manufacturer.

Can I switch from Ozempic to Wegovy? Yes. If you are on Ozempic for diabetes and want more weight loss, ask your provider about switching to Wegovy 2.4 mg. Some insurers cover the switch; others deny it. If denied, compounded semaglutide 2.4 mg is an alternative.

Can I switch from Wegovy to compounded semaglutide? Yes. If Wegovy is out of stock or not covered by insurance, you can switch to compounded semaglutide at the same dose. Work with your provider to ensure continuity of dosing and avoid restarting titration.

How long does it take to reach the full Wegovy dose? Wegovy's FDA-approved titration schedule is 16 weeks: 4 weeks each at 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg, then maintenance at 2.4 mg starting week 17. The schedule minimizes nausea and other GI side effects.

How long does it take to reach the full Ozempic dose? Ozempic's typical titration is 4 weeks at 0.25 mg, then escalation to 0.5 mg or 1 mg. If escalating to 2 mg, an additional 4 weeks at 1 mg is recommended. Total titration time to 1 mg is 8 weeks; to 2 mg is 12 weeks.

Which has worse side effects, Wegovy or Ozempic? Side effects are dose-dependent, not brand-dependent. Higher doses cause more nausea, vomiting, and diarrhea. Wegovy's 2.4 mg dose has a higher side effect rate than Ozempic's 1 mg dose in head-to-head comparisons. At the same dose, side effects are equivalent.

Can I take Ozempic and Wegovy at the same time? No. Both contain semaglutide. Taking both would be double-dosing the same medication, which increases the risk of severe hypoglycemia, nausea, vomiting, and pancreatitis. Use one or the other, not both.

Why does my pharmacy have Ozempic but not Wegovy? Novo Nordisk prioritizes Ozempic manufacturing for diabetes patients, who have fewer alternative treatments. Wegovy supply has been constrained since 2021 due to demand exceeding manufacturing capacity. The FDA shortage list reflects this imbalance.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Frías JP et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
8. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
9. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
12. FDA Drug Shortages Database. Semaglutide injection shortage records. Accessed April 2026.
13. Section 503A, Federal Food, Drug, and Cosmetic Act. Pharmacy Compounding regulations.
14. Novo Nordisk. Ozempic Prescribing Information. Revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.